



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 9/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/EP2014/058415

(22) International Filing Date:

25 April 2014 (25.04.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13165676.1 29 April 2013 (29.04.2013) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).(72) Inventors: **BORRONI, Edilio**; Dammerkirchstrasse 70, CH-4056 Basel (CH). **GOBBI, Luca**; Unterer Lehmattweg 19, CH-4463 Buus (CH). **HONER, Michael**; Rebbergstrasse 37, CH-8037 Zuerich (CH). **KNUST, Henner**; Im Ortsetter 26a, 79618 Rheinfelden (DE). **KOERNER, Matthias**; Kolpingstrasse 10, 79639 Grenzach-Wyhlen (DE). **MURI, Dieter**; St. Johannis-Ring 108, CH-4056 Basel (CH).(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES



(57) Abstract: The invention relates to compounds of formulas I and II, formula I or formula II wherein R¹ is hydrogen, lower alkyl, lower alkoxy, halogen, S-lower alkyl, lower alkoxy substituted by halogen, di-lower alkyl amino, C(O)O-lower alkyl, lower alkyl substituted by hydroxy or hydroxy; R² is hydrogen, lower alkyl, halogen, lower alkoxy, S-lower alkyl, lower alkoxy substituted by halogen, O(CH₂)₂-lower alkoxy substituted by halogen, di-lower alkyl amino, alkyl amino, NH-lower alkyl substituted by halogen, N(lower alkyl)-benzyl, lower alkyl substituted by hydroxy, heterocycloalkyl optionally substituted by halogen, CH₂-lower alkoxy, CH₂-lower alkoxy substituted by halogen or hydroxy; or R¹ and R² form together with the carbon atoms to which they are attached a ring containing -OCH₂CH₂O-, OCH₂O-, OCH₂CH₂CH₂O- or -NHC(O)CH₂O-; R³ is hydrogen or lower alkoxy; R⁴ is hydrogen or lower alkyl; R⁵ is lower alkyl, cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or R⁴ and R⁵ form together with the nitrogen atom to which they are attached a ring containing -CH₂CH₂CHRCH₂CH₂-, -CH₂CHRCH₂CH₂-, -CH₂CH₂OCH₂CH₂-, -CH₂CH₂NR'CH₂CH₂-, CH₂CHR- or -CH₂CH₂CH₂-, wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R' is lower alkyl substituted by halogen; R^a is hydrogen or H; R^b is hydrogen, hydroxy or ³H; R⁶ is hydrogen, halogen or lower alkyl; HetAr is selected from the group consisting of thiophenyl, furanyl, thiazolyl, benzofuranyl, pyrazolyl, benzoimidazolyl or pyridinyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The present compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.